Priovant Therapeutics’ Lisraya (brepocitinib) becomes the first oral medicine specifically developed and approved for the rare autoimmune muscle-and-skin disease, following the longest and largest placebo-controlled dermatomyositis trial conducted to date.
The US Food and Drug Administration approved Lisraya (brepocitinib) on 27 August 2026, for the treatment of dermatomyositis in adults — the first medicine ever specifically developed and approved for a disease that has, for decades, been managed almost entirely with corticosteroids and immunosuppressants originally developed for other conditions. The approval was announced directly by the FDA’s Center for Drug Evaluation and Research and welcomed by both the Muscular Dystrophy Association and The Myositis Association, patient organisations that have tracked the drug’s development closely.
Dermatomyositis is a rare autoimmune disease in which the immune system attacks muscle and skin tissue, causing chronic inflammation, progressive muscle weakness and a characteristic skin rash. Because no therapy had previously been developed and tested specifically for the disease, treatment has historically relied on broad-acting immunosuppressive drugs — corticosteroids, methotrexate, intravenous immunoglobulin and others — borrowed from the treatment of different autoimmune conditions, an approach that manages symptoms without addressing dermatomyositis’s specific underlying disease biology and that carries the cumulative side-effect burden of long-term systemic immunosuppression.
How brepocitinib works and what the trial showed
Brepocitinib is an oral, selective inhibitor of tyrosine kinase 2 (TYK2) and Janus kinase 1 (JAK1), two signalling enzymes involved in the inflammatory pathways implicated in dermatomyositis. The approval rested on results from the Phase 3 VALOR trial, described by its investigators as the largest and longest interventional dermatomyositis trial conducted to date, and the first placebo-controlled study in the disease to run a full 52 weeks. Ruth Ann Vleugels, the trial’s first author and chair of dermatology at Brigham and Women’s Hospital, described VALOR as a landmark study when presenting its results earlier this year, noting that the goal was to allow patients to receive a targeted, effective therapy early in their disease course and avoid the cumulative side effects of long-term corticosteroids and other broad immunosuppressants.
FDA officials framed the approval in similar terms. Nikolay Nikolov, director of the FDA’s Office of Immunology and Inflammation, said in the agency’s approval announcement that patients with dermatomyositis had for too long faced a significant unmet need for effective treatments, often relying on therapies meant for other diseases, and described the approval as a meaningful step forward that gives patients and their healthcare providers an approved oral therapy proven to help manage the disease. Priovant Therapeutics, the drug’s developer, has said Lisraya is available immediately in the United States.
Why it matters
Dermatomyositis is rare, but its burden on the patients who have it is severe and often lifelong: progressive muscle weakness can affect swallowing and breathing in advanced cases, the characteristic skin involvement is frequently disfiguring and socially isolating, and long-term corticosteroid use — the mainstay of treatment until now — carries well-documented risks including osteoporosis, diabetes, cataracts and increased infection risk. A therapy developed and tested specifically for the disease, rather than repurposed from elsewhere, represents a different order of treatment than an incremental improvement on existing options; it is the first time dermatomyositis patients have had access to a medicine whose efficacy and safety profile were established in their specific condition rather than extrapolated from other autoimmune diseases.
The approval also carries a broader signal for rare-disease drug development. TYK2/JAK1 inhibition is a mechanism already used more broadly in other autoimmune and inflammatory conditions, and a successful, dedicated Phase 3 programme in a disease as rare as dermatomyositis — affecting a small enough population that recruiting a trial large enough to be statistically convincing over 52 weeks is itself a significant undertaking — demonstrates that well-designed rare-disease trials in this drug class remain commercially and scientifically viable, a consideration relevant to companies weighing whether to pursue dedicated development programmes for other understudied autoimmune conditions. As with any newly approved therapy, real-world safety and effectiveness data gathered over the coming years, across a broader and more diverse patient population than a controlled trial, will be needed to fully establish brepocitinib’s risk-benefit profile outside trial conditions. The approval is a US one; Indian regulatory review and eventual availability, as this publication has noted with other recently approved US therapies, typically follow by a year or considerably more, if they follow at all for a rare-disease drug of this kind serving a small global patient population.
– Rithvisha Kiran
Key facts
– Drug: Lisraya (brepocitinib), an oral TYK2/JAK1 inhibitor developed by Priovant Therapeutics
– FDA approved 27 August 2026 as the first targeted therapy specifically developed for dermatomyositis in adults
– Based on the Phase 3 VALOR trial (n=241) — the longest (52-week) and largest placebo-controlled dermatomyositis trial conducted to date
– Previously, treatment relied entirely on corticosteroids and immunosuppressants developed for other autoimmune diseases
– Available immediately in the United States per Priovant Therapeutics; no international regulatory approvals reported yet
